前列腺癌，癌症疫苗，胜肽:藥物開發策略分析 是由出版商BioSeeker Group AB在2011年11月所出版的。
這份英文市場調查報告書包含2403 Pages 價格從美金5175起跳。
本報告以前列腺癌的藥物開發策略和癌症疫苗的機制、目標、影響領域及胜肽的化合物領域為焦點，彙整各種的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等彙整資料，為您概述為以下內容。
第1章 前列腺癌
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的前列腺癌治療藥物目標策略
- 使用中的化合物策略:前列腺癌治療藥物各化合物策略競爭基準
- 開發平台及最佳投資組合:前列腺癌治療藥物開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 癌症疫苗
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的癌症疫苗治療藥劑目標策略
- 使用中的化合物策略:各化合物策略競爭基準
- 癌症疫苗的癌適應症症狀選擇
- 開發平台及最佳投資組合:癌症疫苗開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
第3章 胜肽
- 本報告的範圍
- 胜肽治療藥物的優點與缺點
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的胜肽藥劑目標策略
- 為了開發藥劑的癌症病狀的選擇
- 開發平台及最佳投資組合:腫瘤學的胜肽開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
Abstract
This triple analysis focuses on cancer drug development strategies in one
specific cancer indication (Prostate Cancer), one mechanism/target/effect area
(Cancer Vaccines) and one compound specific area (Peptides). Each of these
three individual parts is evaluated according to standardized criteria in a
five pillar pipeline drug assessment methodology to compare drug development
strategies in oncology. This makes it easy to find and compare analysis not
only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Prostate Cancer
The prostate cancer report part comprises defined and up to date development
strategies for 346 prostate cancer drugs within the portfolio of 198
investigators, from Ceased to Marketed. This report part extensively analyses
202 identified targets of prostate cancer drugs, organized into 187 drug
target strategies, and assesses them in prostate cancer.
Part II: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development
strategies for 155 cancer vaccine drugs within the portfolio of 99
investigators, from Ceased to Marketed. This part extensively analyses their
94 identified drug targets, organized into 91 drug target strategies, and
assesses them in 42 different cancer indications.
Part III: Peptides
The cancer peptide drug report part comprises defined and up to date
development strategies for 152 peptide drugs in oncology within the portfolio
of 104 companies world-wide, from Ceased to Marketed. The report extensively
analyses their 123 identified drug targets, organized into 103 drug target
strategies, and assesses them in 56 cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Prostate Cancer
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (202 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies by
their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug
Target Strategies and 346 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Prostate
Cancer Drugs by Compound Strategy (8 Different Compound Strategies)
- 9. Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate
Cancer Therapeutic Pipeline by Investigator (198 Investigators)
- 11. Drug Index
- 12. Company Index
- Figures: Includes 6 Figures
- Tables: Includes 257 Tables
- Total Number of Pages: 838
Part II: Cancer Vaccines
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target Among Cancer Vaccine Drugs for the
Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target
Strategies and 155 Cancer Vaccine Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine
Drugs by Compound Strategy (7 Compound Strategies)
- 9. Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer
Indications)
- 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Cancer Vaccine Drug Pipeline by Investigator (99 Investigators)
- 11. Disclaimer
- 12. Drug Index
- 13. Company Index
- Figures: Includes 6 Figures
- Tables: Includes 205 Tables
- Total Number of Pages: 659
Part III: Peptides
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target Among Peptide Drugs in Oncology for the
Highest Therapeutic Outcome and Return on Investment (123 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Peptide Drugs in Oncology by their Highest Stage of Development (103 Drug
Targets Strategies and 152 Peptide Drugs)
- 8. Selecting Indication for Peptide Drugs in Oncology (56 Cancer
Indications)
- 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Peptide Drug Pipeline in Oncology by Investigator (104 Investigators and 152
Peptide Drugs)
- 10. Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 5 Figures
- Tables: Includes 207 Tables
- Total Number of Pages: 906
This Report Includes the Following Companies:
- 7TM Pharma
- Abbott
- Abraxis BioScience
- AC Immune
- Acceleron Pharma
- Active Biotech
- Adaptimmune
- Aduro BioTech
- Advantagene
- Advaxis
- AEgera
- AEterna Zentaris
- Affymax
- Aida Pharmaceuticals
- Aileron Therapeutics
- Akela Pharma
- Alchemia
- Allos Therapeutics
- Allostera
- Allosterix
- AlphaVax
- Alseres Pharmaceuticals
- Altor BioScience
- Ambrilia Biopharma
- Amgen
- Anavex Life Sciences
- Anchor Therapeutics
- AngioChem
- Angstrom Pharmaceuticals
- Antisense Pharma
- Antisoma
- Aphios
- AplaGen Biopharmaceuticals
- ApopLogic Pharmaceuticals
- Apotex
- Apthera
- Archer Biosciences
- Ardana
- Ariad
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- AstraZeneca
- Attenuon
- AVI BioPharma
- Bavarian Nordic
- Baxter International
- Bayer
- Bellicum Pharmaceuticals
- Bioenvision
- Biogen Idec
- Biokine Therapeutics
- BioLineRx
- Biostar
- BioVex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Cadila
- CanBas
- Cancer Advances
- Cancer Innovations
- Cancer Research Technology
- CDG Therapeutics
- Cel-Sci
- Celecure
- Cell Genesys
- Cell Therapeutics
- Celldex Therapeutics
- Celsion
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemGenex Pharmaceuticals
- Chemokine Therapeutics
- Circadian Technologies
- Cleveland BioLabs
- Clinuvel
- Compugen
- Cosmo Pharmaceuticals
- CSL
- Curaxis
- Cyclacel
- Cylene Pharmaceuticals
- Cytokinetics
- Daiichi Sankyo
- Debiopharm
- Dendreon
- DeveloGen
- Diatos
- Digna Biotech
- Dongkook Pharm
- ECI
- Eisai
- Elan
- Eli Lilly
- Endo Pharmaceuticals
- Endocyte
- Enkam Pharmaceuticals
- EntreMed
- Epeius Biotechnologies
- EpiCept
- Esperance Pharmaceuticals
- EUSA Pharma
- Exelixis
- Galena Biopharma
- Gemin X Biotechnologies
- Generex
- GenOdyssee Pharmaceuticals
- GENova Biotherapeutics
- Genovax
- Genta
- GENTICEL
- Genzyme
- Geron
- GlaxoSmithKline
- Gliknik
- GlobeImmune
- Gloucester Pharmaceuticals
- GlycoGenesys
- Got-a-Gene
- GP Pharm
- Gradalis
- Green Cross
- Gryphon Therapeutics
- Hoffmann-La Roche
- Human Genome Sciences
- Ichor Medical Systems
- Idera Pharmaceuticals
- ImmunoCellular Therapeutics
- Immunocore
- ImmunoFrontier
- ImmunoGen
- Immunomedics
- Immunotope
- ImmuPharma
- Incyte Corporation
- Infinity Pharmaceuticals
- Innate Pharma
- Innovive
- Inovio
- Insmed
- Introgen Therapeutics
- Ipsen
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- Ivy Medical Chemicals
- Johnson & Johnson
- Karyon-CTT
- Kyowa Hakko Kirin
- LEAD Therapeutics
- Lee's Pharmaceutical
- Ligand
- Lorus Therapeutics
- Mannkind
- Marillion Pharmaceuticals
- MBiotec
- Meda
- Medarex
- Medical Marketing International
- MediGene
- MedImmune
- Mediolanum
- Menarini
- Merck & Co
- Merck KGaA
- MethylGene
- Micromet
- Mojave Therapeutics
- MolMed
- Mologen
- Nektar Therapeutics
- Nemod Biotherapeutics
- NeoPharm
- Neovacs
- Nerviano Medical Sciences
- Neurobiological Technologies
- Nidus Laboratories
- Nippon Shinyaku
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- Novartis
- NovaRx
- Novogen
- NPS Pharmaceuticals
- OncoGenex Pharmaceuticals
- OncoMune
- OncoTherapy Science
- Oncothyreon
- Oncovir
- Onyvax
- Orion Pharma
- OSI Pharmaceuticals
- Oxford BioMedica
- Paladin Labs
- Pantarhei Bioscience
- Pepscan Systems
- Pepscan Therapeutics
- Peptagen
- PepTx
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pierre Fabre
- Prima Biomed
- Progen
- Progenics Pharmaceuticals
- ProNAi Therapeutics
- ProStrakan
- Protagonist
- Protherics
- Protox Therapeutics
- Q Chip
- QLT
- Radient Pharmaceuticals
- Raptor Pharmaceutical
- Receptor BioLogix
- Regeneron
- Regulon
- responsif
- Rexahn
- Samyang
- Sanofi-Aventis
- Santaris Pharma
- Scancell
- SciClone Pharmaceuticals
- Semafore Pharmaceuticals
- Serometrix
- Shire
- Soligenix
- Spectrum Pharmaceuticals
- SRI International
- SuperGen
- Supratek Pharma
- Switch Pharma
- Takeda
- TapImmune
- Tau Therapeutics
- Thallion Pharmaceuticals
- Therion Biologics
- Theryte
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- TopoTarget
- Transgene
- Unigene
- United Biomedical
- Vaccinex
- Vaxil BioTherapeutics
- Vaxon Biotech
- VaxOnco
- Vectura
- Vical
- Wilex
- Vion Pharmaceuticals
- VioQuest
- Viragen
- Viralytics
- Virionics
- ViroMed
- ViroTarg
- Xerion
- Xigen
- Xoma
- YM BioSciences
- Zelos Therapeutics
- Zensun
A Shortlist of Drugs Included are:
- A6
- abarelix
- abiraterone acetate
- ABT-510
- ADXS11-001
- AE-37
- AEZS-108
- afamelanotide
- aflibercept
- ALVAC-CEA/B7.1
- angiopep+paclitaxel
- astuprotimut-r
- AVX-701
- belagenpumatucel-L
- bevacizumab
- bicalutamide
- BP-GMAX-CD1
- buserelin
- Cadi-05
- CB-10-01
- CBP-501
- CEA-TRICOM
- celecoxib
- CG-201
- CMLVAX-100
- corticorelin acetate
- CTL901
- CTP-37
- CVac
- dasatinib
- DCVax-prostate
- degarelix
- denosumab
- deslorelin
- docetaxel
- dutasteride
- E-75
- emepepimut-S
- estramustine phosphate sodium
- ethinyl estradiol sulfonate
- flutamide
- fowlpox-PSA vaccine
- goserelin
- GRNVAC1
- GV-1001
- GV-1002
- GVAX
- GVX-3322
- GX-301
- Her-2/Neu peptides
- histrelin
- IGN-101
- imMucin
- ImmunoVEX tri-melan
- IMO-2055
- INGN-225
- ipilimumab
- IPP-204106
- ISA-P53-01
- leuprolide
- leuprolide acetate
- MAGE-3-TK
- MDV-3100
- MDX-1379
- ME-103
- MGN-1601
- MSI vaccine
- MVA-BN
- MVA-BN Her-2 vaccine
- nadroparin
- NAFB001
- netupitant
- nilutamide
- Norelin
- Onyvax-105
- OTS-102
- ozarelix
- PANVAC-VF
- pasireotide
- pasireotide LAR
- pDOM-PSMA27
- PEP-223
- poly-ICLC
- PR1:169-177 peptide
- PROSTVAC
- PX-104.1
- Reximmune-C
- rindopepimut
- romurtide
- SAI-EGF
- sotatercept
- Stimuvax
- sunitinib malate
- TG-4001
- TG-4010
- thymalfasin
- tigapotide triflutate
- TM-30339
- toremifene citrate
- triptorelin
- triptorelin pamoate
- TroVax
- verpasep caltespen
- VX-001
- zibotentan
- ZYC-300
